Report Detail

Request for Sample of this report

Other Global RNAi for Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM2940171
    • |
  • 11 January, 2024
    • |
  • Global
    • |
  • 115 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Other

According to our (Global Info Research) latest study, the global RNAi for Therapeutic market size was valued at USD 181.1 million in 2023 and is forecast to a readjusted size of USD 2031.2 million by 2030 with a CAGR of 41.2% during review period.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Global RNAi for Therapeutic key players include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, etc. Global top five manufacturers hold a share over 85%.
US is the largest market, with a share over 75%, followed by EU, which has a share about 3%.
In terms of product, siRNA is the largest segment, with a share over 55%. And in terms of application, the largest application is Cancer, followed by HBV, Cardiovascular, etc.
The Global Info Research report includes an overview of the development of the RNAi for Therapeutic industry chain, the market status of Cancer (siRNA, miRNA), Cardiovascular (siRNA, miRNA), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of RNAi for Therapeutic.
Regionally, the report analyzes the RNAi for Therapeutic markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global RNAi for Therapeutic market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the RNAi for Therapeutic market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the RNAi for Therapeutic industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., siRNA, miRNA).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the RNAi for Therapeutic market.
Regional Analysis: The report involves examining the RNAi for Therapeutic market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the RNAi for Therapeutic market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to RNAi for Therapeutic:
Company Analysis: Report covers individual RNAi for Therapeutic players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards RNAi for Therapeutic This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Cancer, Cardiovascular).
Technology Analysis: Report covers specific technologies relevant to RNAi for Therapeutic. It assesses the current state, advancements, and potential future developments in RNAi for Therapeutic areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the RNAi for Therapeutic market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
RNAi for Therapeutic market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
siRNA
miRNA
shRNA
Market segment by Application
Cancer
Cardiovascular
HBV
Others
Market segment by players, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe RNAi for Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of RNAi for Therapeutic, with revenue, gross margin and global market share of RNAi for Therapeutic from 2019 to 2024.
Chapter 3, the RNAi for Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and RNAi for Therapeutic market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of RNAi for Therapeutic.
Chapter 13, to describe RNAi for Therapeutic research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of RNAi for Therapeutic
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of RNAi for Therapeutic by Type
    • 1.3.1 Overview: Global RNAi for Therapeutic Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global RNAi for Therapeutic Consumption Value Market Share by Type in 2023
    • 1.3.3 siRNA
    • 1.3.4 miRNA
    • 1.3.5 shRNA
  • 1.4 Global RNAi for Therapeutic Market by Application
    • 1.4.1 Overview: Global RNAi for Therapeutic Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Cancer
    • 1.4.3 Cardiovascular
    • 1.4.4 HBV
    • 1.4.5 Others
  • 1.5 Global RNAi for Therapeutic Market Size & Forecast
  • 1.6 Global RNAi for Therapeutic Market Size and Forecast by Region
    • 1.6.1 Global RNAi for Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global RNAi for Therapeutic Market Size by Region, (2019-2030)
    • 1.6.3 North America RNAi for Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.4 Europe RNAi for Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific RNAi for Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.6 South America RNAi for Therapeutic Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa RNAi for Therapeutic Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Alnylam Pharmaceuticals
    • 2.1.1 Alnylam Pharmaceuticals Details
    • 2.1.2 Alnylam Pharmaceuticals Major Business
    • 2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Product and Solutions
    • 2.1.4 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
  • 2.2 Arbutus Biopharma (Tekmira)
    • 2.2.1 Arbutus Biopharma (Tekmira) Details
    • 2.2.2 Arbutus Biopharma (Tekmira) Major Business
    • 2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Product and Solutions
    • 2.2.4 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Arbutus Biopharma (Tekmira) Recent Developments and Future Plans
  • 2.3 Arrowhead
    • 2.3.1 Arrowhead Details
    • 2.3.2 Arrowhead Major Business
    • 2.3.3 Arrowhead RNAi for Therapeutic Product and Solutions
    • 2.3.4 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Arrowhead Recent Developments and Future Plans
  • 2.4 Dicerna Pharmaceuticals
    • 2.4.1 Dicerna Pharmaceuticals Details
    • 2.4.2 Dicerna Pharmaceuticals Major Business
    • 2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Product and Solutions
    • 2.4.4 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
  • 2.5 Mirna Therapeutics
    • 2.5.1 Mirna Therapeutics Details
    • 2.5.2 Mirna Therapeutics Major Business
    • 2.5.3 Mirna Therapeutics RNAi for Therapeutic Product and Solutions
    • 2.5.4 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Mirna Therapeutics Recent Developments and Future Plans
  • 2.6 Quark Pharmaceuticals
    • 2.6.1 Quark Pharmaceuticals Details
    • 2.6.2 Quark Pharmaceuticals Major Business
    • 2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Product and Solutions
    • 2.6.4 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Quark Pharmaceuticals Recent Developments and Future Plans
  • 2.7 RXi Pharmaceuticals
    • 2.7.1 RXi Pharmaceuticals Details
    • 2.7.2 RXi Pharmaceuticals Major Business
    • 2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Product and Solutions
    • 2.7.4 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 RXi Pharmaceuticals Recent Developments and Future Plans
  • 2.8 Silence Therapeutics
    • 2.8.1 Silence Therapeutics Details
    • 2.8.2 Silence Therapeutics Major Business
    • 2.8.3 Silence Therapeutics RNAi for Therapeutic Product and Solutions
    • 2.8.4 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Silence Therapeutics Recent Developments and Future Plans
  • 2.9 Benitec Biopharma
    • 2.9.1 Benitec Biopharma Details
    • 2.9.2 Benitec Biopharma Major Business
    • 2.9.3 Benitec Biopharma RNAi for Therapeutic Product and Solutions
    • 2.9.4 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 Benitec Biopharma Recent Developments and Future Plans
  • 2.10 miRagen Therapeutics
    • 2.10.1 miRagen Therapeutics Details
    • 2.10.2 miRagen Therapeutics Major Business
    • 2.10.3 miRagen Therapeutics RNAi for Therapeutic Product and Solutions
    • 2.10.4 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 miRagen Therapeutics Recent Developments and Future Plans
  • 2.11 Sylentis
    • 2.11.1 Sylentis Details
    • 2.11.2 Sylentis Major Business
    • 2.11.3 Sylentis RNAi for Therapeutic Product and Solutions
    • 2.11.4 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 Sylentis Recent Developments and Future Plans
  • 2.12 Gradalis
    • 2.12.1 Gradalis Details
    • 2.12.2 Gradalis Major Business
    • 2.12.3 Gradalis RNAi for Therapeutic Product and Solutions
    • 2.12.4 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 Gradalis Recent Developments and Future Plans
  • 2.13 Sirnaomics
    • 2.13.1 Sirnaomics Details
    • 2.13.2 Sirnaomics Major Business
    • 2.13.3 Sirnaomics RNAi for Therapeutic Product and Solutions
    • 2.13.4 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 Sirnaomics Recent Developments and Future Plans
  • 2.14 Silenseed
    • 2.14.1 Silenseed Details
    • 2.14.2 Silenseed Major Business
    • 2.14.3 Silenseed RNAi for Therapeutic Product and Solutions
    • 2.14.4 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Silenseed Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global RNAi for Therapeutic Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of RNAi for Therapeutic by Company Revenue
    • 3.2.2 Top 3 RNAi for Therapeutic Players Market Share in 2023
    • 3.2.3 Top 6 RNAi for Therapeutic Players Market Share in 2023
  • 3.3 RNAi for Therapeutic Market: Overall Company Footprint Analysis
    • 3.3.1 RNAi for Therapeutic Market: Region Footprint
    • 3.3.2 RNAi for Therapeutic Market: Company Product Type Footprint
    • 3.3.3 RNAi for Therapeutic Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global RNAi for Therapeutic Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global RNAi for Therapeutic Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global RNAi for Therapeutic Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global RNAi for Therapeutic Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America RNAi for Therapeutic Consumption Value by Type (2019-2030)
  • 6.2 North America RNAi for Therapeutic Consumption Value by Application (2019-2030)
  • 6.3 North America RNAi for Therapeutic Market Size by Country
    • 6.3.1 North America RNAi for Therapeutic Consumption Value by Country (2019-2030)
    • 6.3.2 United States RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 6.3.3 Canada RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico RNAi for Therapeutic Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe RNAi for Therapeutic Consumption Value by Type (2019-2030)
  • 7.2 Europe RNAi for Therapeutic Consumption Value by Application (2019-2030)
  • 7.3 Europe RNAi for Therapeutic Market Size by Country
    • 7.3.1 Europe RNAi for Therapeutic Consumption Value by Country (2019-2030)
    • 7.3.2 Germany RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.3 France RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.5 Russia RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 7.3.6 Italy RNAi for Therapeutic Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific RNAi for Therapeutic Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific RNAi for Therapeutic Market Size by Region
    • 8.3.1 Asia-Pacific RNAi for Therapeutic Consumption Value by Region (2019-2030)
    • 8.3.2 China RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.3 Japan RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.5 India RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 8.3.7 Australia RNAi for Therapeutic Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America RNAi for Therapeutic Consumption Value by Type (2019-2030)
  • 9.2 South America RNAi for Therapeutic Consumption Value by Application (2019-2030)
  • 9.3 South America RNAi for Therapeutic Market Size by Country
    • 9.3.1 South America RNAi for Therapeutic Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina RNAi for Therapeutic Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa RNAi for Therapeutic Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa RNAi for Therapeutic Market Size by Country
    • 10.3.1 Middle East & Africa RNAi for Therapeutic Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia RNAi for Therapeutic Market Size and Forecast (2019-2030)
    • 10.3.4 UAE RNAi for Therapeutic Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 RNAi for Therapeutic Market Drivers
  • 11.2 RNAi for Therapeutic Market Restraints
  • 11.3 RNAi for Therapeutic Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 RNAi for Therapeutic Industry Chain
  • 12.2 RNAi for Therapeutic Upstream Analysis
  • 12.3 RNAi for Therapeutic Midstream Analysis
  • 12.4 RNAi for Therapeutic Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on RNAi for Therapeutic . Industry analysis & Market Report on RNAi for Therapeutic is a syndicated market report, published as Global RNAi for Therapeutic Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of RNAi for Therapeutic market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,208.56
    		4,812.84
    		6,417.12
    		531,604.80
    		797,407.20
    		1,063,209.60
    		292,702.80
    		439,054.20
    		585,405.60
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo